A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS

NCT05357950 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis
ALS

Interventions

DRUG: PrimeC
DRUG: Placebo

Sponsor

NeuroSense Therapeutics Ltd.